Skip to main content
Oxford Research Peptides
MECHANISM NOTE

GIP Receptor Explained

A concise reference on the glucose-dependent insulinotropic polypeptide receptor — its classification, signalling and role in modern multi-agonist incretin research.

QUICK ANSWER
TL;DR

Quick answer

The GIP receptor (GIPR) is a class B G-protein-coupled receptor activated by the incretin hormone glucose-dependent insulinotropic polypeptide. It signals primarily via Gαs / cAMP and is a shared research target for dual and triple incretin-receptor agonists.
EXTENDED ANSWER
AI-ready

Extended answer

What is the GIP receptor and what role does it play in multi-agonist peptides?

The GIP receptor (GIPR) is a class B secretin-like G-protein-coupled receptor activated by the incretin hormone glucose-dependent insulinotropic polypeptide, a 42-amino-acid peptide released from intestinal K-cells in response to nutrient intake. GIPR couples primarily to Gαs, elevates intracellular cyclic AMP and drives glucose-dependent insulin secretion from pancreatic β-cells, with additional reported effects in adipose tissue and the central nervous system. Historically GLP-1R was the sole incretin-family target for peptide-drug research; adding GIPR engagement gives the dual agonist Tirzepatide its distinctive pharmacological profile, and Retatrutide extends this further by combining GIPR with GLP-1R and GCGR activity in one molecule. In-vitro potency at GIPR is typically characterised in recombinant HEK293 or CHO systems using cAMP-response readouts.
KEY FACTS

Key facts

Receptor class
Class B GPCR (secretin-like)
Endogenous ligand
GIP (1-42)
Primary coupling
Gαs / cAMP
Research family
Incretin mimetics

Definition · GIP (glucose-dependent insulinotropic polypeptide)

A 42-amino-acid peptide hormone released from intestinal K-cells in response to nutrient ingestion and, alongside GLP-1, one of the two principal incretin hormones.

Classification

GIPR belongs to the class B (secretin-like) G-protein-coupled receptor family. Like the other class B GPCRs it uses a large extracellular N-terminal domain to capture its peptide ligand and stabilise the active receptor conformation.[6]

Endogenous ligand and signalling

The endogenous ligand at GIPR is GIP (1-42), released from intestinal K-cells after nutrient intake.[4]Activation engages Gαs, elevates intracellular cyclic AMP and drives glucose-dependent insulin secretion from pancreatic β-cells alongside additional effects on adipose tissue and the central nervous system.

Why GIPR matters in multi-agonist research

Historically, GLP-1R was the sole incretin-family target for peptide-drug research. Adding GIPR engagement gives the dual agonist Tirzepatide its distinctive pharmacological profile, and Retatrutide extends this further by combining GIPR with GLP-1R and GCGR activity in a single molecule.[1]

  • Single-agonist (GLP-1R): Semaglutide-class analogues.
  • Dual-agonist (GLP-1R + GIPR): Tirzepatide.
  • Triple-agonist (GLP-1R + GIPR + GCGR): Retatrutide.[1]

Working with GIPR in vitro

Recombinant human GIPR expressed in HEK293 or CHO cell lines is a common substrate for functional cAMP assays. When benchmarking new analogues, matching the receptor construct, tag and readout used in the primary literature enables direct comparison of reported potency values.

Where to go next

References6

  1. 1.

    Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metabolism. 2022;34(9):1234-1247.

    DOI: 10.1016/j.cmet.2022.07.013PMID: 35985340
  2. 2.

    Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.

    DOI: 10.1056/NEJMoa2301972PMID: 37366315
  3. 3.

    Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.. The Lancet. 2023;402(10401):529-544.

    DOI: 10.1016/S0140-6736(23)01053-XPMID: 37385275
  4. 4.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  5. 5.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  6. 6.

    de Graaf C, Donnelly D, Wootten D, et al.. Glucagon-like peptide-1 and its class B G protein–coupled receptors: a long march to therapeutic successes.. Pharmacological Reviews. 2016;68(4):954-1013.

    DOI: 10.1124/pr.115.011395PMID: 27736833
EVIDENCE SUMMARY
Evidence

Evidence summary

Strong evidence
Research confidenceHigh confidence
GIPR is a well-characterised receptor with extensive independent literature spanning incretin physiology, structural biology and pharmacology.
RELATED GUIDES
COMPOUNDS TARGETING GIPR
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-07-15
Updated
2026-07-15
Reviewed
2026-07-15
Version
1.0

Revision history

  1. v1.02026-07-15· Editorial Team

    Initial publication as part of the Retatrutide authority cluster (Release 4.0).

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-01-15. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-07-15Updated: 2026-07-15